2024
Evaluation of the study of control arms in randomized clinical trials of cancer.
Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.Peer-Reviewed Original ResearchRandomized clinical trialsSystemic anti-cancer therapyCancer randomized clinical trialsControl armSuccess rateClinical trials of cancerFisher's exact testAnti-cancer therapyTrial success ratesStudy publication yearExact testPatient convenienceRegimensClinical trialsHighest success rateExperimental armCancer typesCancerContext of treatmentPublication yearTrialsDoseNon-cancerEfficacyDyads
2012
Radon and lung cancer.
Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology And Oncology 2012, 10: 157-64. PMID: 22402423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerTobacco smokeSmoking cessation measuresIndependent risk factorLung cancer deathsCancer prevention effortsCancer-related deathCessation measuresMechanisms of carcinogenesisCancer deathRisk factorsNumerous cohortsCancerPrevention effortsRadon exposureCausative effectReactive oxygen speciesCarcinogenic potentialCommon mechanismDeathOxygen speciesDNA damageCauseRadon mitigationSmoke